SK697A3 - Method for preparing 4-acetoxy-2'alpha'-benzoyloxy-5'beta',20- -epoxy-1,7'beta',10'beta'-trihydroxy-9-oxo-tax-11-en-13'alpha'- -yl(2r,3s)-3-tert-butoxycarbonylamino-2-hydroxy-3- -phenylpropionate trihydrate - Google Patents

Method for preparing 4-acetoxy-2'alpha'-benzoyloxy-5'beta',20- -epoxy-1,7'beta',10'beta'-trihydroxy-9-oxo-tax-11-en-13'alpha'- -yl(2r,3s)-3-tert-butoxycarbonylamino-2-hydroxy-3- -phenylpropionate trihydrate Download PDF

Info

Publication number
SK697A3
SK697A3 SK6-97A SK697A SK697A3 SK 697 A3 SK697 A3 SK 697A3 SK 697 A SK697 A SK 697A SK 697 A3 SK697 A3 SK 697A3
Authority
SK
Slovakia
Prior art keywords
beta
benzoyloxy
trihydroxy
acetoxy
hydroxy
Prior art date
Application number
SK6-97A
Other languages
Slovak (sk)
Other versions
SK280520B6 (en
Inventor
Jean-Rene Authelin
Jacques Doveze
Elie Fouque
Bernadette Mandard
Isabelle Taillepied
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9465183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK697(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of SK697A3 publication Critical patent/SK697A3/en
Publication of SK280520B6 publication Critical patent/SK280520B6/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Epoxy Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

A method for preparing 4-acetoxy-2 alpha -benzoyloxy-5 beta ,20-epoxy-1,7 beta ,10 beta -trihydroxy-9-oxo-tax-11-en-yl-13 alpha (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate trihydrate by crystallisation from a hydroalcoholic solution.

Description

Spôsob prípravy trihydrátu (2R,3S)-4-acetoxy-2a-benzoyloxy-5B120-epoxy-l,7B,10B-trihydroxy-9-oxo-tax-ll-én-13a-yl-3terc.butoxykarbonylamino-2-hydroxy-3-fenylpropionátuA process for the preparation of the trihydrate of (2R, 3S) 4-acetoxy-2-benzoyloxy-5 B 1 20-epoxy-7.beta, 10.beta.-trihydroxy-9-oxo-tax-ll-en-13-yl-2-3terc.butoxykarbonylamino hydroxy-3-phenylpropionate

Oblasť technikyTechnical field

Vynález sa týka spôsobu prípravy trihydrátu 4-acetoxy-2abenzoyloxy-5B,20-epoxy-l,7B,10B-trihydroxy-9-oxo-tax-ll-én-13ayl-3-terc.butoxykarbonylamino-2-hydroxy-3-fenylpropionátu s konfiguráciou (2R,3S).The present invention relates to a process for the preparation of 4-acetoxy-2-benzoyloxy-5B, 20-epoxy-1,7B, 10B-trihydroxy-9-oxo-tax-11-ene-3-yl-3-tert-butoxycarbonylamino-2-hydroxy-3- phenylpropionate (2R, 3S).

Doterajší stav technikyBACKGROUND OF THE INVENTION

V európskych patentoch EP-0 253 738 a EP-0 336 841 je opísaný (2R,3S)-4-acetoxy-2a-benzoyloxy-5B,20-epoxy-l,7B,10Btrihydroxy-9-oxo-tax-ll-én-13a-yl-3-terc.butoxykarbonylamino-EP-0 253 738 and EP-0 336 841 disclose (2R, 3S) -4-acetoxy-2a-benzoyloxy-5B, 20-epoxy-1,7B, 10B-trihydroxy-9-oxo-tax-11- en-13-yl-3-terc.butoxykarbonylamino-

2-hydroxy-3-fenylpropionát, ktorý má protirakovinové a protileukemické vlastnosti, pričom v týchto patentových dokumentoch je tiež opísaný spôsob prípravy tejto zlúčeniny.2-hydroxy-3-phenylpropionate having anti-cancer and anti-leukemic properties, and a process for preparing the compound is also described in these patents.

Zistilo sa, že trihydrát (2R,3S)-4-acetoxy-2a-benzoyloxy5B,20-epoxy-l,7B,10B-trihydroxy-9-oxo-tax-ll-én-13a-yl-3-terc. butoxykarbonylamino-2-hydroxy-3-fenylpropionátu má výrazne lepšiu stabilitu ako rovnaký produkt v bezvodom stave.(2R, 3S) -4-Acetoxy-2a-benzoyloxy-5B, 20-epoxy-1,7B, 10B-trihydroxy-9-oxo-tax-11-en-13a-yl-3-tert. butoxycarbonylamino-2-hydroxy-3-phenylpropionate has significantly better stability than the same anhydrous product.

Podstata vynálezuSUMMARY OF THE INVENTION

Podlá vynálezu sa môže trihydrát (2R,3S)-4-acetoxy-2a-benzoyloxy-5B,20-epoxy-l,7B,10B-trihydroxy-9-oxo-tax-ll-én-13ayl-3-terc .butoxykarbonylamino-2-hydroxy-3-fenylpropionátu získať po kryštalizácii (2R,3S)-4-acetoxy-2a-benzoyloxy-5B,20epoxy-1,7B,10B-trihydroxy-9-oxo-tax-ll-én-13a-yl-3-terc.butoxykarbonylamino-2-hydroxy-3-fenylpropionátu zo zmesi vody a alifatického alkoholu obsahujúceho 1 až 3 atómy uhlíka a následným sušením získaného produktu pri stanovených teplotných, tlakových a vlhkostných podmienok.According to the invention, (2R, 3S) -4-acetoxy-2a-benzoyloxy-5B, 20-epoxy-1,7B, 10B-trihydroxy-9-oxo-tax-11-ene-13ayl-3-tert-butoxycarbonylamino trihydrate can be Of 2-hydroxy-3-phenylpropionate obtained after crystallization of (2R, 3S) -4-acetoxy-2a-benzoyloxy-5B, 20epoxy-1,7B, 10B-trihydroxy-9-oxo-tax-11-en-13a-yl -3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate from a mixture of water and an aliphatic alcohol containing 1 to 3 carbon atoms, followed by drying the product obtained under specified temperature, pressure and humidity conditions.

Po uskutočnení spôsobu podľa vynálezu môže byť výhodné najmä:After carrying out the process according to the invention, it may in particular be advantageous to:

rozpustenie (2R,3S)-4-acetoxy-2a-benzoyloxy-5B,20-epoxy1,7β,106-trihydroxy-9—oxo-tax-ll-én—13a—yl-3-terc.butoxykarbonylamino-2-hydroxy-3-fenylpropionátu, ktorý sa predbežne prečistil chromatograficky, v alifatickom alkohole obsahujúcom 1 až 3 atómy uhlíka pri teplote, ktorá sa pohybuje výhodne medzi 40 a 60 °C,dissolution of (2R, 3S) -4-acetoxy-2a-benzoyloxy-5B, 20-epoxy-1,7β, 106-trihydroxy-9-oxo-tax-11-en-13a-yl-3-tert-butoxycarbonylamino-2-hydroxy -3-phenylpropionate, which has been previously purified by chromatography, in an aliphatic alcohol containing 1 to 3 carbon atoms at a temperature preferably between 40 and 60 ° C,

- prípadné odstránenie zvyškových chromatografických rozpúšťadiel ko-destiláciou pri zníženom tlaku, pričom sa objem oddestilovaného rozpúšťadla nahradí čistým alkoholom,- the optional removal of residual chromatographic solvents by co-distillation under reduced pressure, replacing the volume of the distilled solvent with pure alcohol,

- pridanie prípadne prečistenej vody pri rovnakej teplote,- addition of possibly purified water at the same temperature,

- a po prípadnom vyvolaní kryštalizácie zaočkovaním a ochladení na teplotu blízku 0 °C oddelenie získaných kryštálov trihydrátu (2R,3S)-4-acetoxy-2a-benzoyloxy-56,20-epoxy-l,76,10B-trihydroxy-9-oxo-tax-ll-én-13a-yl-3-terc.butoxykarbonylamino-2-hydroxy-3-fenylpropionátu, ktorý sa takto získal, a následné vysušenie pri zníženom tlaku pod atmosférou s regulovanou vlhkosťou.- and, if necessary, by crystallization by seeding and cooling to a temperature close to 0 ° C, separation of the obtained (2R, 3S) -4-acetoxy-2a-benzoyloxy-56,20-epoxy-1,76,10B-trihydroxy-9-oxo trihydrate crystals -tax-11-en-13a-yl-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate thus obtained, followed by drying under reduced pressure under a controlled humidity atmosphere.

Všeobecne sa (2R,3S)-4-acetoxy-2a-benzoyloxy-56,20-epoxy1,76,10B-trihydroxy-9-oxo-tax-ll-én-13a-yl-3-terc.butoxykarbonylamino-2-hydroxy-3-fenylpropionát v prečistenom stave rozpustí v prebytku alifatického alkoholu. Výhodne je množstvo alkoholu 8 až 12 hmotnostných dielov, vztiahnuté na jeden hmotnostný diel (2R,3S)-4-acetoxy-2a-benzoyloxy-56,20-epoxy1,76,10B-trihydroxy-9-oxo-tax-ll-én-13a-yl-3-terc.butoxykarbony1amino-2-hydroxy-3-fenylpropionátu.Generally, (2R, 3S) -4-acetoxy-2a-benzoyloxy-56,20-epoxy-1,76,10B-trihydroxy-9-oxo-tax-11-en-13a-yl-3-tert-butoxycarbonylamino-2- The hydroxy-3-phenylpropionate is dissolved in the excess aliphatic alcohol in the purified state. Preferably, the amount of alcohol is 8 to 12 parts by weight, based on 1 part by weight of (2R, 3S) -4-acetoxy-2a-benzoyloxy-56,20-epoxy-1,76,10B-trihydroxy-9-oxo-tax-11-ene -13?-yl-3-terc.butoxykarbony1amino-2-hydroxy-3-phenylpropionate.

Všeobecne sa oddestilovanie alkoholu uskutočňuje pri zníženom tlaku pri teplote blízkej 40 °C a to až do okamihu, kedy sa získa hustý sirup, ktorého miešanie je obťažné. Je výhodné opakovať túto operáciu, ktorá vedie k odstráneniu zvyškových rozpúšťadiel obsiahnutých v použitom prečistenom produkte , niekoľkokrát.Generally, the distillation of the alcohol is carried out under reduced pressure at a temperature close to 40 ° C until a thick syrup is obtained which is difficult to mix. It is advantageous to repeat this operation several times to remove residual solvents contained in the purified product used.

Keď sa odstránenie zvyšných rozpúšťadiel ukončí, získaný sirup sa vyberie alkoholom použitom v množstve, ktoré sa rovnáWhen the removal of the remaining solvents is complete, the syrup obtained is taken up with an alcohol used in an amount equal to

3,5 až 6 hmotnostným dielom, vztiahnuté na jeden hmotnostný diel (2R, 3S) -4-acetoxy-2a-benzoyloxy-5B, 20-epoxy-l, 7B, 10B- trihydroxy-9-oxo-tax-11-én-13 α-y 1-3-terc.butoxykarbony1amino-3.5 to 6 parts by weight, based on 1 part by weight of (2R, 3S) -4-acetoxy-2a-benzoyloxy-5B, 20-epoxy-1,7B, 10B-trihydroxy-9-oxo-tax-11-ene -13 α-γ 1-3-tert-butoxycarbonylamino-

2-hydroxy-3-fenylpropionátu.2-hydroxy-3-phenylpropionate.

Po prípadnom odstránení nerozpustných nečistôt filtráciou sa pridá voda, výhodne prečistená, a to v takom množstve, aby hmotnostný pomer voda/alkohol bol blízky hodnote 2/1.After optionally removing the insoluble impurities by filtration, water, preferably purified water, is added in an amount such that the water / alcohol weight ratio is close to 2/1.

Kryštalizácia sa vyvolá zaočkovaním a zmes sa pozvoľne ochladí až na teplotu blízku 0 °C.Crystallization is induced by seeding and the mixture is cooled slowly to a temperature close to 0 ° C.

Vykryštalizovaný trihydrát (2R,3S)-4-acetoxy-2a-benzoyloxy-5B,20-epoxy-l,7B,10B-trihydroxy-9-oxo-tax-ll-én-13a-yl-3terc.butoxykarbonylamino-2-hydroxy-3-fenylpropionátu sa oddelí, výhodne filtráciou alebo odstredením, následne sa vysuší. Sušenie sa uskutočňuje pri zníženom tlaku v rozmedzí medzi 4 a 7 kPa, pri teplote blízkej 40 °C a pod atmosférou s regulovanou vlhkosťou, pričom relatívna vlhkosť je blízka 80 %.Crystallized (2R, 3S) -4-acetoxy-2a-benzoyloxy-5B, 20-epoxy-1,7B, 10B-trihydroxy-9-oxo-tax-11-en-13a-yl-3-tert-butoxycarbonylamino-2- The hydroxy-3-phenylpropionate is separated, preferably by filtration or centrifugation, and subsequently dried. Drying is carried out under reduced pressure between 4 and 7 kPa, at a temperature close to 40 ° C and under a controlled humidity atmosphere, the relative humidity being close to 80%.

Na uskutočnenie spôsobu podľa vynálezu je výhodné uskutočniť kryštalizáciu v prítomnosti kyseliny askorbovej, ktorá sa pridá pri rozpúšťaní prečisteného (2R,3S)-4-acetoxy2a-benzoyloxy-5B,20-epoxy-l,7β,10B-trihydroxy-9-oxo-tax-ll-én13a-yl-3-terc.butoxykarbonylamino-2-hydroxy-3-f enylpropionátu v alkohole. Môže sa použiť až 1 % hmotnosti kyseliny askorbovej .For carrying out the process of the invention, it is preferable to carry out crystallization in the presence of ascorbic acid, which is added in the dissolution of purified (2R, 3S) -4-acetoxy-2? -Benzoyloxy-5B, 20-epoxy-1,7β, 10B-trihydroxy-9-oxo tax-11-en-13a-yl-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate in alcohol. Up to 1% by weight of ascorbic acid may be used.

Na uskutočnenie spôsobu podľa vynálezu je obzvlášť výhodné použiť ako alkohol etanol.It is particularly preferred to use ethanol as the alcohol for carrying out the process according to the invention.

Štruktúra trihydrátu (2R,3S)-4-acetoxy-2a-benzoyloxy-5B,20-epoxy-l,7B,10B-trihydroxy-9-oxo-tax-ll-én-13a-yl-3-terc.butoxykarbonylamino-2-hydroxy-3-fenylpropionátu je potvrdená rôntgenovou difrakciou, termogravimetrickou analýzou a diferenčnou kalorimetrickou analýzou.(2R, 3S) -4-Acetoxy-2a-benzoyloxy-5B, 20-epoxy-1,7B, 10B-trihydroxy-9-oxo-tax-11-en-13a-yl-3-tert-butoxycarbonylamino- 2-hydroxy-3-phenylpropionate is confirmed by X-ray diffraction, thermogravimetric analysis and differential calorimetric analysis.

Takto termogravimetrická analýza ukazuje 6,1% úbytok hmotnosti v rozsahu teplôt medzi 40 a 140 °C, čo zodpovedá trom molekulám vody na jednu molekulu (2R,3S)-4-acetoxy-2abenzoyloxy-5B,20-epoxy-l,7B,10B-trihydroxy-9-oxo-tax-ll-én13a-yl-3-terc.butoxykarbonylamino-2-hydroxy-3-fenylpropionátu.Thus, thermogravimetric analysis shows a 6.1% weight loss in the temperature range between 40 and 140 ° C, corresponding to three water molecules per molecule of (2R, 3S) -4-acetoxy-2-benzoyloxy-5B, 20-epoxy-1,7B, 10.beta.-trihydroxy-9-oxo-tax-ll-EN13-yl-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate.

Metóda stanovenia merného obsahu vody a hydratačnej vody diferenčnou kalorimetrickou analýzou ukazuje neprítomnosť neviazanej vody a endotermický signál pri teplote 132,6 °C zodpovedá disociácii hydrátu.The method of determination of specific water content and hydration water by differential calorimetry analysis shows the absence of unbound water and the endothermic signal at 132.6 ° C corresponds to the dissociation of the hydrate.

Trihydrát (2R,3S)-4-acetoxy-2a-benzoyloxy-5B,20-epoxy1,7B,10B-trihydroxy-9-oxo-tax-ll-én-13a-yl-3-terc.butoxykarbonylamino-2-hydroxy-3-fenylpropionátu už nie je hygroskoPický.(2R, 3S) -4-Acetoxy-2a-benzoyloxy-5B, 20-epoxy-1,7B, 10B-trihydroxy-9-oxo-tax-11-en-13a-yl-3-tert-butoxycarbonylamino-2-hydroxy trihydrate -3-phenylpropionate is no longer hygroscopic.

Štúdie stability ukazujú, že trihydrát (2R,3S)-4-acetoxy2a-benzoyloxy-5B,20-epoxy-l,7B,10B-trihydroxy-9-oxo-tax-ll-én13 α-y1-3-terc.butoxykarbonylamino-2-hydroxy-3-fenylpropionátu ukazujú, že je stabilná pri teplote 4 °C, 25 °C a 35 °C v atmosfére s 90% relatívnou vlhkosťou až počas 18 mesiacov, bez toho, aby v priebehu tohto času prišlo k modifikácii jeho kryštalickej formy.Stability studies show that (2R, 3S) -4-acetoxy-2a-benzoyloxy-5B, 20-epoxy-1,7B, 10B-trihydroxy-9-oxo-tax-11-ene-13-γ-3-tert-butoxycarbonylamino trihydrate -2-hydroxy-3-phenylpropionate show that it is stable at 4 ° C, 25 ° C and 35 ° C in an atmosphere with 90% relative humidity for up to 18 months without any modification of its crystalline form.

Pri rovnakých podmienkach prechádza (2R,3S)-4-acetoxy-2abenzoyloxy-5B,20-epoxy-l,7B,10B-trihydroxy-9-oxo-tax-ll-én-13ayl-3-terc.butoxykarbonylamino-2-hydroxy-3-fenylpropionát v bezvodej forme, ktorý má odlišnú kryštalickú formu, pozvoľna do trihydrátovej formy.Under the same conditions, (2R, 3S) -4-acetoxy-2-benzoyloxy-5B, 20-epoxy-1,7B, 10B-trihydroxy-9-oxo-tax-11-ene-13ayl-3-tert-butoxycarbonylamino-2- hydroxy-3-phenylpropionate in anhydrous form, which has a different crystalline form, is slowly formed into the trihydrate form.

V nasledujúcej časti opisu bude vynález bližšie objasnený pomocou príkladov jeho konkrétneho uskutočnenia, pričom tieto príklady majú len ilustračný charakter a nijako neobmedzujú rozsah vynálezu, ktorý je jednoznačne definovaný formuláciou patentových nárokov.In the following, the invention will be explained in more detail by way of examples of a specific embodiment thereof, these examples being illustrative only and not in any way limiting of the scope of the invention, which is clearly defined by the wording of the claims.

Príklady uskutočnenia vynálezuDETAILED DESCRIPTION OF THE INVENTION

Príklad 1Example 1

Do reaktora bez prístupu svetla sa zavedie 303 g (2R,3S)-303 g of (2R, 3S) -

4-acetoxy-2a-benzoyloxy-5B,20-epoxy-l,7β,10B-trihydroxy-9-oxotax-ll-én-13a-yl-3-terc.butoxykarbonylamino-2-hydroxy-3-fenylpropionátu s čistotou 92,4 % (0,314 molu) a 2,875 kg absolút- neho etanolu (d = 0,79). Získaná zmes sa zohrieva na teplotu 40 °C až do okamihu, kedy sa dosiahne úplne rozpustenie (2R,3S)-4-acetoxy-2a-benzoyloxy-5fi,20-epoxy-l, 7B,10B-trihydroxy-9oxo-tax-ll-én-13a-yl-3-terc.butoxykarbonylamino-2-hydroxy-3fenylpropionátu. Potom sa destiluje etanol pri zníženom tlaku 12 kPa až do okamihu, kedy sa získa sirup, ktorý je na samej hranici miešateľnosti. K sirupu sa pridá 0,983 kg etanolu a destilácia sa opakuje pri rovnakých podmienkach. K získanému sirupu sa pridá 1,257 kg etanolu a zmes sa zohrieva na teplotu 50 °C až do úplného rozpustenia pevného podielu. Zmes sa prefiltruje za tepla, následne sa k filtrátu pridá v priebehu jednej hodiny 4,39 kg prečistenej vody pri udržovaní teploty 50 °C. Po vyvolaní kryštalizácie zaočkovaním sa zmes ochladí na teplotu 0 eC v priebehu 4 hodín. Vylúčené kryštály sa oddelia filtráciou, premyjú 0,909 kg a potom 0,606 kg zmesi etanolu a vody v hmotnostnom pomere 1:2, následne sa vysušia pri teplote 38 °C pri zníženom tlaku (5,07 kPa) v atmosfére s 80% relatívnou vlhkosťou v priebehu 48 hodín. Takto sa získa4-Acetoxy-2a-benzoyloxy-5B, 20-epoxy-1,7β, 10B-trihydroxy-9-oxotax-11-en-13a-yl-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate with a purity of 92 , 4% (0.314 mol) and 2.875 kg of absolute ethanol (d = 0.79). The resulting mixture is heated to 40 ° C until complete dissolution of (2R, 3S) -4-acetoxy-2α-benzoyloxy-5α, 20-epoxy-1,7B, 10B-trihydroxy-9oxo-tax- ll-en-13-yl 3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate. Ethanol is then distilled under reduced pressure of 12 kPa until a syrup is obtained which is at the very limit of miscibility. 0.983 kg of ethanol are added to the syrup and the distillation is repeated under the same conditions. 1.257 kg of ethanol are added to the obtained syrup and the mixture is heated to 50 ° C until the solid is completely dissolved. The mixture is filtered hot, then 4.39 kg of purified water are added to the filtrate over one hour, maintaining the temperature at 50 ° C. After initiating the crystallization, the mixture was cooled to 0 and C for 4 hours. The separated crystals are collected by filtration, washed with 0.909 kg and then 0.606 kg of a 1: 2 mixture of ethanol and water, then dried at 38 ° C under reduced pressure (5.07 kPa) in an atmosphere with 80% relative humidity during 48 hours. This is obtained

266,5 g trihydrátu (2R,3S)-4-acetoxy-2a-benzoyloxy-5B,20-epoxy1,7β,10B-trihydroxy-9-oxo-tax-ll-én-13a-yl-3-terc.butoxykarbonylamino-2-hydroxy-3-fenylpropionátu, pri ktorom sa vysokovýkonnou kvapalinovou chromátografiou stanovila čistota 98,8 % (táto čistota sa vzťahuje k sušine), pričom obsah vody je 6,15 %.266.5 g of (2R, 3S) -4-acetoxy-2a-benzoyloxy-5B, 20-epoxy-1,7β, 10B-trihydroxy-9-oxo-tax-11-en-13a-yl-3-tert-butoxycarbonylamino trihydrate 2-hydroxy-3-phenylpropionate, in which a purity of 98.8% (purity related to dry weight) was determined by high performance liquid chromatography, the water content being 6.15%.

Príklad 2Example 2

Pri teplote blízkej 35 °C sa 110,0 g (2R,3S)-4-acetoxy-2abenzoyloxy-5B,20-epoxy-l,7B,10fi-trihydroxy-9-oxo-tax-ll-én-13ayl-3-terc.butoxykarbonylamino-2-hydroxy-3-fenylpropionátu s čistotou 92,5 % a 0,2224 g kyseliny askorbovej rozpustí v 1340 cm3 etanolu. Oddestiluje sa asi 70 % zavedeného etanolu pri zníženom tlaku (8 kPa) a pri teplote blízkej 20 °C. Zmes sa zohreje na 50 °C a prefiltruje. Filtrát sa trikrát premyje vždy 70,5 cm3 etanolu, následne sa k nemu pridá v priebehu Ϊ5 minút 860,5 cm3 prečistenej vody a to pri teplote 50 °C. Roztok sa zaočkuje niekoľkými kryštálmi trihydrátu (2R,3S)-4acetoxy-2a-benzoyloxy-5B,20-epoxy-l,7B,10B-trihydroxy-9-oxotax-11-én-13 α-y1-3-terc.butoxykarbonylamino-2-hydroxy-3-feny 1propionátu a zmes sa mieša počas 30 minút. Potom sa v priebehu 3 hodín pridá 860,5 cm3 prečistenej vody pri teplote 50 °C, následne sa zmes v priebehu 3 hodín ochladí až na teplotu blízku 0 °C. Suspenzia sa prefiltruje a filtračný koláč sa premyje 330 g zmesi vody a etanolu v hmotnostnom pomere 2:1, následne sa koláč premyje ešte 220 g rovnakej zmesi a potom sa vysuší pri zníženom tlaku (5 kPa) pri teplote 38 °C v atmosfére s 80% relatívnou vlhkosťou. Takto sa získa vo výtažku 98 % 110,2 g trihydrátu (2R,3S)-4-acetoxy-2a-benzoyloxy-5B,20-epoxy-l,7B,10B-trihydroxy-9-oxo-tax-ll-én-13a-yl-3terc.butoxykarbonylamino-2-hydroxy-3-fenylpropionátu.At a temperature close to 35 ° C, 110.0 g of (2R, 3S) -4-acetoxy-2-benzoyloxy-5B, 20-epoxy-1,7B, 10β-trihydroxy-9-oxo-tax-11-en-13ayl-3 of tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate with a purity of 92.5% and 0.2224 g of ascorbic acid are dissolved in 1340 cm 3 of ethanol. About 70% of the ethanol introduced is distilled off under reduced pressure (8 kPa) at a temperature close to 20 ° C. The mixture was heated to 50 ° C and filtered. The filtrate is washed three times with 70.5 cm 3 of ethanol each, followed by 605.5 cm 3 of purified water at 50 ° C over minút5 minutes. The solution is seeded with several crystals of (2R, 3S) -4-acetoxy-2a-benzoyloxy-5B, 20-epoxy-1,7B, 10B-trihydroxy-9-oxotax-11-en-13 α-γ-3-tert-butoxycarbonylamino trihydrate Of 2-hydroxy-3-phenylpropionate and the mixture is stirred for 30 minutes. Thereafter, 860.5 cm @ 3 of purified water are added at 50 DEG C. over a period of 3 hours, followed by cooling to a temperature in the region of 0 DEG C. over 3 hours. The suspension is filtered and the filter cake is washed with 330 g of a 2: 1 mixture of water and ethanol, followed by washing of the cake with 220 g of the same mixture and then dried under reduced pressure (5 kPa) at 38 ° C under 80 % relative humidity. 110.2 g of (2R, 3S) -4-acetoxy-2a-benzoyloxy-5B, 20-epoxy-1,7B, 10B-trihydroxy-9-oxo-tax-11-ene- trihydrate are thus obtained in 98% yield. 13 3terc.butoxykarbonylamino-yl-2-hydroxy-3-phenylpropionate.

Claims (5)

PATENTOVÉ NÁROKYPATENT CLAIMS 1. Spôsob prípravy trihydrátu (2R,3S)-4-acetoxy-2a-benzoyloxy-5B, 20-epoxy-l,7B,10B-trihydroxy-9-oxo-tax-ll-én-13a-yl-3terc.butoxykarbonylamino-2-hydroxy-3-fenylpropionátu, vyznačený tým, že sa (2R,3S)-4-acetoxy-2a-benzoyloxy-5B, 20-epoxy-l,7B,10B-trihydroxy-9-oxo-tax-ll-én-13a-yl-3terc.butoxykarbonylamino-2-hydroxy-3-fenylpropionát nechá vykryštalizovať zo zmesi vody a alifatického alkoholu obsahujúceho 1 až 3 atómy uhlíka, následne sa získaný produkt vysuší pri stanovených teplotných, tlakových a vlhkostných podmienkach.A process for the preparation of (2R, 3S) -4-acetoxy-2a-benzoyloxy-5B, 20-epoxy-1,7B, 10B-trihydroxy-9-oxo-tax-11-en-13a-yl-3-tert-butoxycarbonylamino trihydrate -2-hydroxy-3-phenylpropionate, characterized in that (2R, 3S) -4-acetoxy-2a-benzoyloxy-5B, 20-epoxy-1,7B, 10B-trihydroxy-9-oxo-tax-11- The en-13a-yl-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate is crystallized from a mixture of water and an aliphatic alcohol containing 1 to 3 carbon atoms, and the product obtained is then dried under the specified temperature, pressure and humidity conditions. 2. Spôsob podlá nároku 1, vyznačený tým, že hmotnostný pomer voda/alkohol je blízky hodnote 2/1.Method according to claim 1, characterized in that the water / alcohol weight ratio is close to 2/1. 3. Spôsob podlá niektorého z nárokov la2, vyznačený t ý m, že alkoholom je etanol.Method according to any one of claims 1 to 2, characterized in that the alcohol is ethanol. 4. Spôsob podlá nároku 1, vyznačený tým, že sušenie sa uskutočňuje pri teplote blízkej 40 °C, pri tlaku medzi 4a 7 kPa a v atmosfére s relatívnou vlhkosťou blízkou 80 %.Method according to claim 1, characterized in that the drying is carried out at a temperature close to 40 ° C, at a pressure between 4 and 7 kPa and in an atmosphere with a relative humidity close to 80%. 5. Spôsob podlá nároku 1, vyznačený tým, že kryštalizácia sa uskutočňuje v prítomnosti kyseliny askorbovej.A process according to claim 1, characterized in that the crystallization is carried out in the presence of ascorbic acid.
SK6-97A 1994-07-08 1995-07-07 Method for preparing 4-acetoxy-2alpha-benzoyloxy-5alpha,20- -epoxy-1,7beta,10beta-trihydroxy-9-oxo-tax-11-en-13alpha- -yl(2r,3s)-3-tert-butoxycarbonylamino-2-hydroxy-3- -phenylpropionate trihydrate SK280520B6 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9408479A FR2722191B1 (en) 1994-07-08 1994-07-08 PROCESS FOR THE PREPARATION OF (2R, 3S) -3-TERTBUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE (2R, 3S) TRIHYDRATE, 20EPOXY-11BYA -13ALPHA-YLE
PCT/FR1995/000910 WO1996001815A1 (en) 1994-07-08 1995-07-07 METHOD FOR PREPARING 4-ACETOXY-2α-BENZOYLOXY-5β,20-EPOXY-1,7β,10β-TRIHYDROXY-9-OXO-TAX-11-EN-13α-YL(2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE TRIHYDRATE

Publications (2)

Publication Number Publication Date
SK697A3 true SK697A3 (en) 1997-06-04
SK280520B6 SK280520B6 (en) 2000-03-13

Family

ID=9465183

Family Applications (1)

Application Number Title Priority Date Filing Date
SK6-97A SK280520B6 (en) 1994-07-08 1995-07-07 Method for preparing 4-acetoxy-2alpha-benzoyloxy-5alpha,20- -epoxy-1,7beta,10beta-trihydroxy-9-oxo-tax-11-en-13alpha- -yl(2r,3s)-3-tert-butoxycarbonylamino-2-hydroxy-3- -phenylpropionate trihydrate

Country Status (38)

Country Link
US (1) US6022985A (en)
EP (1) EP0770070B1 (en)
JP (1) JP3753155B2 (en)
KR (1) KR100391753B1 (en)
CN (1) CN1067996C (en)
AT (1) ATE171702T1 (en)
AU (1) AU706519B2 (en)
BR (1) BR9508789A (en)
CA (1) CA2193531C (en)
CO (1) CO4410189A1 (en)
CZ (1) CZ284695B6 (en)
DE (1) DE69505128T2 (en)
DK (1) DK0770070T3 (en)
DZ (1) DZ1905A1 (en)
ES (1) ES2121404T3 (en)
FI (1) FI119246B (en)
FR (1) FR2722191B1 (en)
GR (1) GR3027558T3 (en)
HU (1) HU220634B1 (en)
IL (1) IL114274A (en)
IN (1) IN183947B (en)
IS (1) IS2032B (en)
MA (1) MA23606A1 (en)
MX (1) MX9700173A (en)
MY (1) MY118481A (en)
NO (1) NO314500B1 (en)
NZ (1) NZ289455A (en)
PE (1) PE8697A1 (en)
PL (1) PL179876B1 (en)
RU (1) RU2126397C1 (en)
SI (1) SI0770070T1 (en)
SK (1) SK280520B6 (en)
TN (1) TNSN95071A1 (en)
TW (1) TW419473B (en)
UA (1) UA51624C2 (en)
UY (1) UY23991A1 (en)
WO (1) WO1996001815A1 (en)
ZA (1) ZA955646B (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU753781B2 (en) 1997-04-28 2002-10-31 Aventis Pharma S.A. Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
SE510650C2 (en) * 1997-05-30 1999-06-14 Astra Ab New association
FR2794771B1 (en) 1999-06-11 2001-08-10 Aventis Pharma Sa RECOMBINANT ADENOVIRUSES ENCODING THE IODINE SPECIFIC TRANSPORTER (NIS)
US6853921B2 (en) 1999-07-20 2005-02-08 Halliburton Energy Services, Inc. System and method for real time reservoir management
US6266619B1 (en) * 1999-07-20 2001-07-24 Halliburton Energy Services, Inc. System and method for real time reservoir management
GB9920548D0 (en) * 1999-08-31 1999-11-03 Rhone Poulenc Rorer Sa Treatment of hepatocellular carcinoma
US6891050B2 (en) * 2001-08-10 2005-05-10 Dabur India Limited Process for the preparation of taxanes such as paclitaxel, docetaxel and structurally similar analogs
US6881852B2 (en) * 2002-02-05 2005-04-19 Dabur India Limited Process of purification of paclitaxel and docetaxel
US7247738B2 (en) * 2002-05-07 2007-07-24 Dabur India Limited Method of preparation of anticancer taxanes using 3-[(substituted-2-trialkylsilyl) ethoxycarbonyl]-5-oxazolidine carboxylic acids
US6900342B2 (en) * 2002-05-10 2005-05-31 Dabur India Limited Anticancer taxanes such as paclitaxel, docetaxel and their structural analogs, and a method for the preparation thereof
US6838569B2 (en) * 2002-12-16 2005-01-04 Dabur India Limited Process for preparation of paclitaxel trihydrate and docetaxel trihydrate
US7584165B2 (en) * 2003-01-30 2009-09-01 Landmark Graphics Corporation Support apparatus, method and system for real time operations and maintenance
US8703982B2 (en) 2003-03-17 2014-04-22 Phyton Holdings Llc Purification of taxanes
CN1268619C (en) * 2003-05-08 2006-08-09 上海迪赛诺化学制药有限公司 Prepn of polyene taxol trihydrate
FR2859996B1 (en) * 2003-09-19 2006-02-03 Aventis Pharma Sa ACETONIC SOLVAT OF DIMETHOXY DOCETAXEL AND PROCESS FOR PREPARING THE SAME
EP1947094A3 (en) 2003-12-12 2009-02-18 Quiral Quimica Do Brasil Process for the preparation of taxane derivatives
US7142986B2 (en) * 2005-02-01 2006-11-28 Smith International, Inc. System for optimizing drilling in real time
CN100420681C (en) * 2005-04-29 2008-09-24 上海奥锐特国际贸易有限公司 Production of polyenoic taxad alcohol trihydrate
CN101291658B (en) 2005-08-31 2014-04-16 阿布拉科斯生物科学有限公司 Compositions and methods for preparing poorly water-soluble drugs with increased stability
US7771751B2 (en) 2005-08-31 2010-08-10 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
WO2007044950A2 (en) * 2005-10-12 2007-04-19 Sicor, Inc. Crystalline forms of docetaxel and processes for their preparation
KR100995390B1 (en) 2006-01-02 2010-11-19 주식회사 삼양제넥스 Method for preparation of amorphous anhydrous crystalline or hydrated crystalline docetaxel
WO2007084611A2 (en) * 2006-01-20 2007-07-26 Landmark Graphics Corporation Dynamic production system management
KR20080100264A (en) * 2006-03-21 2008-11-14 닥터 레디스 레보러터리즈 리미티드 Polymorphs of Docetaxel and Manufacturing Method Thereof
EP2330101A1 (en) * 2006-10-20 2011-06-08 Scinopharm Singapore Pte, Ltd. Process for making crystalline docetaxel
KR100868116B1 (en) * 2007-04-09 2008-11-10 한미약품 주식회사 Docetaxel-monopropylene glycol-containing compound and preparation method thereof
KR100878455B1 (en) 2007-04-10 2009-01-13 한미약품 주식회사 Stable anhydrous docetaxel and preparation method thereof
WO2009006590A2 (en) * 2007-07-04 2009-01-08 Dr. Reddy's Laboratories Ltd. Docetaxel process and polymorphs
EP2080763A1 (en) * 2008-01-18 2009-07-22 INDENA S.p.A. Crystalline form I of ortataxel
EP2080764B1 (en) 2008-01-18 2012-08-22 INDENA S.p.A. Solid forms of ortataxel
PL388144A1 (en) 2009-05-29 2010-12-06 Przedsiębiorstwo Produkcyjno-Wdrożeniowe Ifotam Spółka Z Ograniczoną Odpowiedzialnością (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate 4-acetoxy-2?-benzoiloxy-5� ,20-epoxy-1, 7�, 10�-trihydroxy-9-oxo-taks-11 -en-13?-yl solvates, a method for their production and application thereof
US8686165B2 (en) * 2009-11-04 2014-04-01 Emcure Pharmaceuticals Limited Process for preparation of taxane derivatives
JP5824511B2 (en) 2010-05-03 2015-11-25 テイコク ファーマ ユーエスエー インコーポレーテッド Non-aqueous taxane proemulsion formulations and methods for preparing and using the same
WO2012160568A1 (en) * 2011-05-23 2012-11-29 Shilpa Medicare Limited Process for preparing docetaxel trihydrate polymorph
ES2704632T3 (en) 2011-09-08 2019-03-19 Univ New York Oncolytic herpes simplex virus and its therapeutic uses
US9745631B2 (en) 2011-12-20 2017-08-29 Dana-Farber Cancer Institute, Inc. Methods for diagnosing and treating oncogenic kras-associated cancer
EP2833905B1 (en) 2012-04-04 2018-05-02 Halozyme, Inc. Combination therapy with hyaluronidase and a tumor-targeted taxane
AU2013266243A1 (en) 2012-05-24 2014-12-18 Beth Israel Deaconess Medical Center, Inc. Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-associated cancer
WO2014014518A1 (en) 2012-07-18 2014-01-23 Dana-Farber Cancer Institute, Inc. Methods for treating, preventing and predicting risk of developing breast cancer
JO3685B1 (en) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc Non-aqueous taxane nanodispersion formulations and methods of using the same
US10238723B2 (en) 2013-03-14 2019-03-26 Icahn School Of Medicine At Mount Sinai Autologous tumor lysate-loaded dendritic cell vaccine for treatment of liver cancer
WO2015050844A1 (en) 2013-10-01 2015-04-09 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds
WO2015149006A2 (en) 2014-03-27 2015-10-01 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating ncoa4-mediated autophagic targeting of ferritin
MA39818A (en) 2014-03-30 2017-02-08 Benevir Biopharm Inc Exogenous tap inhibitor "armed" oncolytic viruses and therapeutic uses thereof
EP3307330B1 (en) 2015-06-15 2021-03-10 New York University Method of treatment using oncolytic viruses
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (en) * 1986-07-17 1988-09-23 Rhone Poulenc Sante TAXOL DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5229526A (en) * 1991-09-23 1993-07-20 Florida State University Metal alkoxides

Also Published As

Publication number Publication date
IL114274A0 (en) 1995-10-31
FI119246B (en) 2008-09-15
BR9508789A (en) 1997-10-21
UA51624C2 (en) 2002-12-16
DK0770070T3 (en) 1999-03-01
SK280520B6 (en) 2000-03-13
NO970007D0 (en) 1997-01-02
PL179876B1 (en) 2000-11-30
DE69505128T2 (en) 1999-04-01
TNSN95071A1 (en) 1996-02-06
DZ1905A1 (en) 2002-02-17
MY118481A (en) 2004-11-30
KR100391753B1 (en) 2004-02-11
IL114274A (en) 1999-04-11
UY23991A1 (en) 1995-09-20
CO4410189A1 (en) 1997-01-09
FR2722191A1 (en) 1996-01-12
HU9700041D0 (en) 1997-02-28
CA2193531C (en) 2006-12-05
CN1151741A (en) 1997-06-11
FI970069L (en) 1997-01-07
CZ3597A3 (en) 1997-04-16
FI970069A0 (en) 1997-01-07
MX9700173A (en) 1997-04-30
WO1996001815A1 (en) 1996-01-25
CN1067996C (en) 2001-07-04
JPH10502627A (en) 1998-03-10
KR970704721A (en) 1997-09-06
ES2121404T3 (en) 1998-11-16
ATE171702T1 (en) 1998-10-15
IN183947B (en) 2000-05-20
AU2930595A (en) 1996-02-09
JP3753155B2 (en) 2006-03-08
AU706519B2 (en) 1999-06-17
GR3027558T3 (en) 1998-11-30
PE8697A1 (en) 1997-03-26
EP0770070A1 (en) 1997-05-02
ZA955646B (en) 1996-02-21
RU2126397C1 (en) 1999-02-20
EP0770070B1 (en) 1998-09-30
CA2193531A1 (en) 1996-01-25
IS2032B (en) 2005-08-15
NO970007L (en) 1997-01-02
PL318195A1 (en) 1997-05-26
US6022985A (en) 2000-02-08
MA23606A1 (en) 1996-04-01
NO314500B1 (en) 2003-03-31
TW419473B (en) 2001-01-21
HU220634B1 (en) 2002-03-28
NZ289455A (en) 1997-12-19
HUT76833A (en) 1997-11-28
FR2722191B1 (en) 1996-08-23
CZ284695B6 (en) 1999-02-17
SI0770070T1 (en) 1998-12-31
IS4411A (en) 1997-01-07
DE69505128D1 (en) 1998-11-05

Similar Documents

Publication Publication Date Title
SK280520B6 (en) Method for preparing 4-acetoxy-2alpha-benzoyloxy-5alpha,20- -epoxy-1,7beta,10beta-trihydroxy-9-oxo-tax-11-en-13alpha- -yl(2r,3s)-3-tert-butoxycarbonylamino-2-hydroxy-3- -phenylpropionate trihydrate
USRE36433E (en) Process for the purifying of iopamidol
EP0976750A1 (en) Novel z-valacyclovir crystals
JP3521242B2 (en) Purification method of biscresols
US6037494A (en) Process for the crystallization from a linear or branched (C5-C6) alcohol or their mixtures of (S)-N,N'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[(2-hydroxy-1-oxopropyy l)amino]-2,4,6-triiodo-1,3-benzendicarboxamide
US5338869A (en) Hydroxyphenylpropionic ester having novel crystal structure
US4868312A (en) N.sup.ε -trifluoroacetyl-L-lysyl-L-proline.D-10-camphorsulfonic acid salt and process for producing the same
SU1034605A3 (en) Process for preparing molecular compound of beta-diethylaminoethylamide of n-chloroacetic phenoxy acid with 4-n-butyl-3,5-diketo-1,2-diphenylpyrazolidine
JP4694018B2 (en) Method for purifying mevalolactone methacrylate
US6235775B1 (en) Acetone adduct of fungicidal V-28-3M
JPH10109991A (en) Production of dimethylamine-borane
JPH07224052A (en) Method for purifying 2-oxetanone
WO2016142173A1 (en) 4-(2-methyl-1h-imidazol-1-yl)-2,2-diphenylbutanenitrile solid form
CN109879739A (en) A kind of refining methd of terephthalaldehyde
CS254347B2 (en) Method of 19-deoxyagglycondianemycine's water-free sodium salt production
JPH09157268A (en) Production of 7-hydroxyisoflavone and its purification
MXPA97007146A (en) Procedure for the obtaining of dimethylaminobor
JPH023628A (en) Production of optically active 1-methyl-3-phenylpropylamine
KR20000053467A (en) Process for recrystallizing 1,3-bis(aminophenoxy benzene)
CS233413B1 (en) Method of purification of 2-chloro-5- [1-hydroxy-3-oxo-1-isoindolinyl] benzanesulfonamide
JPWO1999014225A1 (en) Acetone adduct of antifungal agent V-28-3M
JPH0135820B2 (en)
JPS5837307B2 (en) L-pyroglutamyl-L-histidyl-L-prolinamide/L-pyroglutamate
JPH06135918A (en) Method for separating N, O-dialkylhydroxylamine hydrochloride

Legal Events

Date Code Title Description
QB4A Licence contract registered or granted

Free format text: EXCLUSIVE LICENCE

Name of requester: MAY & BAKER LTD., WEST MALLING, KENT, GB

Effective date: 20070101

Free format text: NON-EXCLUSIVE LICENCE

Name of requester: SANOFI-AVENTIS PHARMA SLOVAKIA S.R.O., BRATISL, SK

Effective date: 20100420

MK4A Patent expired

Expiry date: 20150707